British drug regulators have granted approval to Advanced Cell Technology to conduct the first trial in Europe of human embryonic stem cells, testing the cells in people with a progressive form of blindness, the firm said on Thursday. Reuters Health …
Month: September 2011
Canon CR-2 PLUS Non-mydriatic Retinal Camera Coming to U.S.
Having secured FDA clearance, Canon is now releasing its CR-2 PLUS digital non-mydriatic retinal camera to the U.S. market. The main feature of the camera over the CR-2 model is its ability to do fundus autofluorescence photography that is used to detect macular residue such as lipofuscin that gathers in the retinal pigment epithelial layer.
Like s (Read more...)
New Twist Uncovered In A Blindness-Causing Disease Gene
After more than three decades of research, University of Pennsylvania veterinarians and vision-research scientists, with associates at Cornell University, have identified a gene responsible for a blindness-inducing disease that afflicts dogs. In the pr…
STAAR’s new Visian ICL with CentraFLOW technology showcased at ESCRS congress
STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced the Visian Implantable Collamer Lens (ICL), and new Visian ICL with CentraFLOW technology utilizing the KS-AquaPORT, were …
Stem Cells in Ophthalmology Update 10: ACT Expands Trials for Embryonic Stem Cells for Stargardt’s to the UK
In a news announcement today, Advanced Cell Technology said it had received approval to expand its stem cell treatment for Stargardt’s Macular Dystrophy to Moorfield’s Hospital in the UK.As reported by the Guardian, “The Massachusetts-based compa…
U.S. Department of Veterans Affairs ceases use of bevacizumab for wet AMD while it investigates reports of increased risk of infection
Source: Reuters Health News
Area: News
According to a Reuters report, the U.S. Department of Veterans Affairs has stopped using bevacizumab to treat wet age-related macular degeneration while it investigates reports of increased risk of infection. Onc…
First European Human Embryonic Stem Cell Trial Gets Go Ahead
The European authorities have given the go ahead for trials to treat patients with Stargardt’s Macular Dystrophy (SMD) using retinal pigment epithelium (RPE) derived from human embryonic stem cells (hESCs). If successful, the trial may pave the way…
AGTC receives FFB grant to evaluate gene therapy treatment for X-linked Retinoschisis
Applied Genetic Technologies Corporation, a privately-held, clinical stage biotechnology company developing novel systems to deliver human therapeutics, announces that it has received a grant of $1.5 million from the Foundation Fighting Blindness to fu…
Patients and Populations: Public Health in Medical Education
VEGF-Trap Beats Laser Again In Diabetic Macular Edema
Ophthalmology: Several injection protocols were tested against laser for diabetic retinopathy. The 2mg every four weeks protocol demonstrated the best results. All protocols beat laser. Again, it looks like for those who don’t reject injections (many of my patients shudder at the thought), VEGF-Trap is the way to go, and hopefully this formula will require […]
OPKO Announces Sale of Ophthalmic Instrumentation Business
MIAMI–(BUSINESS WIRE)–OPKO Health, Inc. (NYSE: OPK) has agreed to sell its ophthalmic instrumentation business to OPTOS, Inc., a subsidiary of Optos plc, a leading and rapidly growing medical technology company engaged in the design, development, man…
Ivantis Announces Results of Hydrus Implant Study
Last week, Ivantis announced the 6-month results from its multi-center, international Hydrus I study at the European Society of Cataract and Refractive Surgery Meeting (ESCRS). The Hydrus(TM) Intracanalicular Implant, roughly the size of an eyelash, is placed through a minimally invasive, microsurgical procedure and is designed to reduce eye pressure by reestablishing the patient’s conventional […]
AGTC Receives Grant from the Foundation Fighting Blindness for Pre-Clinical Study of Gene Therapy for Eye Disease
GAINESVILLE, Fla.–(BUSINESS WIRE)–AGTC receives significant grant funding from the Foundation Fighting Blindness to develop treatment for genetic eye disease, XLRS, causing blindness in young boys.
Canaloplasty an Option in Open-Angle Glaucoma
Canaloplasty works just as well as trabeculectomy in reducing intraocular pressure (IOP) in patients with open-angle glaucoma, according to a comparative case series in Ophthalmology.
IRIDEX licenses rights to Ocunetics’ intellectual property
IRIDEX Corporation today announced that it has exclusively licensed the rights to all of the intellectual property of Ocunetics, Inc., a privately held company based in Alamo, California. Ocunetics develops procedure-enabling medical devices that are …
Canaloplasty an Option in Open-Angle Glaucoma
Canaloplasty works just as well as trabeculectomy in reducing intraocular pressure (IOP) in patients with open-angle glaucoma, according to a comparative case series in Ophthalmology. Reuters Health Information
US FDA approves denosumab for cancer therapy-induced bone loss in women with breast cancer and men with prostate cancer
Source: BioSpace.com
Area: News
The US Food and Drug Administration (FDA) has approved denosumab (Prolia) as a treatment, for the following indications:
. to increase bone mass in women at high risk for fracture receiving adjuvant aromatase in…
Social Media Primer for Healthcare Professionals
Popular social media sites can benefit healthcare professionals, if used appropriately. Find out how. Medscape Public Health
ERWW PR forms Health Buzz Group
Euro RSCG Worldwide PR (ERWW PR) announces the formation of its Health Buzz Group, a global division created in response to growing client interest in big, splashy “wows” from small budgets in quick time frames using traditional and social media to…